Related Condition
Mold Exposure, CIRS & ME/CFS: The Full Landscape
Mold-related illness sits at a genuine crossroads of emerging science, patient advocacy, institutional skepticism, and contested evidence. This section covers the complete picture - the Shoemaker/CIRS framework, the formal criticisms of it, the mainstream medicine position, and all major alternative approaches to mold illness - without dismissing patient experiences or overstating scientific consensus.
- CIRS (Chronic Inflammatory Response Syndrome) from mold in water-damaged buildings overlaps extensively with ME/CFS symptoms.
- Key red flag: symptoms that improve significantly when away from a specific building for 1-2 weeks.
- The Shoemaker Protocol is the only published CIRS treatment with clinical efficacy evidence - but all evidence comes from Shoemaker's own group, with no independent RCTs.
- Urine mycotoxin testing (RealTime Labs, Mosaic) is not FDA-approved; Shoemaker himself does not endorse it as CIRS diagnostics.
- Start with: HERTSMI-2 building test ($150-200) and VCS screening ($15 at survivingmold.com) before spending thousands on blood panels.
- The universally supported step regardless of framework: remove yourself from any water-damaged environment.
What Is CIRS? The Shoemaker Framework
CIRS (Chronic Inflammatory Response Syndrome) was characterized by Dr. Ritchie Shoemaker, a family physician in Maryland, beginning in 1997. He linked an outbreak of illness to the dinoflagellate Pfiesteria, then subsequently connected similar multi-system illness to mold in water-damaged buildings, tick-borne disease, cyanobacteria, and other biotoxin sources.[103,104]
The core Shoemaker mechanism: certain biotoxins are lipid-soluble and in genetically susceptible individuals (approximately 24% of the population based on specific HLA haplotypes) cannot be properly cleared by the immune system. Rather than being tagged with antibodies and removed, these biotoxins recirculate continuously, driving chronic innate immune activation and a cascade of downstream hormonal, neurological, and inflammatory abnormalities across at least 13 identifiable symptom clusters.[104]
CIRS vs ME/CFS: Similarities and Distinctions
| Feature | CIRS (Shoemaker) | ME/CFS |
|---|---|---|
| Core symptoms | Fatigue, brain fog, cognitive impairment, pain, mood symptoms, shortness of breath, GI symptoms - overlaps extensively with ME/CFS | PEM (cardinal feature), unrefreshing sleep, profound fatigue, cognitive impairment, orthostatic intolerance |
| Proposed cause | Biotoxin exposure from water-damaged buildings, tick-borne pathogens, marine biotoxins | Post-infectious trigger (typically viral); immune dysregulation; multifactorial |
| Diagnostic biomarkers | Proprietary panel: MSH, VIP, VEGF, TGF-beta-1, MMP-9, C4a, ACTH/cortisol, ADH/osmolality; 4 of 8 must be abnormal - per Shoemaker criteria | No validated diagnostic biomarker panel; diagnosis by clinical criteria (IOM 2015) |
| Treatment | 12-step Shoemaker Protocol; environmental removal is foundational; cholestyramine/binders; sequential hormonal restoration | No curative treatment; pacing foundational; symptom management |
| Misdiagnosis direction | Frequently misdiagnosed as ME/CFS, fibromyalgia, depression, Lyme | Frequently misdiagnosed as depression, anxiety, somatization |
| Genetic susceptibility | HLA haplotypes; ~24% susceptible per Shoemaker's population data[104] | Modest heritability from DecodeME; no single susceptibility gene identified[11] |
| Mainstream acceptance | Not recognized by CDC, NIH, or major academic medical centers; no published independent RCTs | Recognized by WHO (ICD-11 G93.32), CDC, NIH, NICE, all major medical authorities |
When to Consider CIRS Evaluation
Shoemaker CIRS Diagnosis: Testing
- Visual Contrast Sensitivity (VCS) Test - neurological function test; ~$15 at survivingmold.com; not specific to CIRS but abnormal in the majority of CIRS patients; a useful and low-cost starting point
- Symptom cluster analysis - 6 of 13 CIRS clusters is suspicious; 8 of 13 is considered confirmatory alongside exposure history
- HERTSMI-2 building test - dust sample to Mycometrics; DNA analysis of 5 key mold species; score above 15 indicates hazardous building for susceptible individuals
- ERMI (Environmental Relative Moldiness Index) - broader EPA-developed test; 36 mold species; score above 2 is Shoemaker's cutoff for reactive patients
- MSH (Melanocyte-Stimulating Hormone) - low MSH hallmark; drives fatigue, pain, sleep problems, hormonal abnormalities
- C4a - complement split product; elevated in active CIRS and also in Lyme, infections
- TGF-beta-1 - elevated; drives autoimmune-type inflammation; regulatory T-cell deficiency
- VEGF - often low in CIRS; reduces oxygen delivery to tissues
- MMP-9 - elevated; breaks down extracellular tissue; drives inflammation
- VIP (Vasoactive Intestinal Peptide) - low; contributes to autonomic and pulmonary symptoms
- HLA typing - identifies susceptibility haplotype; guides prognosis
- NeuroQuant MRI - volumetric brain MRI showing edema and atrophy patterns attributed to CIRS neuroinflammation
The Shoemaker 12-Step Protocol
Step 1: Remove from Biotoxin Exposure
The non-negotiable first step. No pharmaceutical intervention will succeed during active exposure. May require professional remediation or vacating a building entirely. Environmental testing (HERTSMI-2, ERMI) guides the decision.
Step 2: Bind and Clear Biotoxins
Cholestyramine (prescription bile acid sequestrant) or Welchol (gentler option) administered 4 times daily away from food and medications. Binds biotoxins recycling through bile in the gut, preventing re-absorption. Often produces the first noticeable symptom improvement. Preceded by high-dose EPA/DHA fish oil to prime the immune system.
Steps 3-4: Eradicate MARCoNS; Address Gluten Sensitivity
MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staphylococci) are detected via deep nasal swab (DLM Lab, MA). If present with 2+ antibiotic resistance classes, treated with BEG spray (bacitracin, EDTA, gentamicin compounded nasal spray). Elevated antigliadin antibodies prompt a 3-month minimum gluten elimination trial.
Steps 5-7: Correct ADH, Androgen, and MMP-9 Abnormalities
ADH/osmolality dysregulation (present in 60%+ of CIRS patients) causes excessive thirst and urination; treated with desmopressin (DDAVP) if needed, with sodium monitoring. Aromatase enzyme overactivity causes low androgens; VIP nasal spray corrects this downstream. Elevated MMP-9 treated with low-amylose diet and high-dose fish oil.
Steps 8-12: Correct VEGF, VIP, and Achieve Full Homeostasis
Low VEGF (reduced capillary oxygen delivery) addressed with losartan. VIP nasal spray (vasoactive intestinal peptide, compounded) is the final-stage treatment; restores hormonal, autonomic, and immune balance. Final clearance of MARCoNS confirmed. Return to safe environment verified. Full lab panel normalization is the treatment endpoint.
Formal Criticisms of the Shoemaker/CIRS Framework
- No independent RCTs: The entire CIRS evidence base comes primarily from Shoemaker's own clinical data, case series, and publications. No large independent randomized controlled trial has tested the Shoemaker Protocol. The 2024 PubMed literature review supporting the protocol was authored by practitioners who serve as expert witnesses in CIRS litigation cases - a significant conflict of interest disclosed in the paper itself.[103]
- Circular validation: The biomarkers, diagnostic criteria, and treatment protocol were all developed and validated within the same group. Critics argue this creates confirmation bias - the researchers define what CIRS is, define what tests diagnose it, and evaluate whether their own treatment works.
- Lab standardization problems: The key biomarkers (C4a, MSH, TGF-beta-1, VIP) are not standardized across reference laboratories. Results vary significantly depending on which lab is used. Without standardized reference ranges validated across independent populations, the biomarker panel cannot be considered clinically validated in the traditional sense.[105]
- Non-specific biomarkers: MSH, C4a, and MMP-9 are not specific to CIRS. They are elevated or dysregulated in many inflammatory conditions including ME/CFS, Lyme disease, autoimmune disease, and general chronic illness. Their abnormality alone does not confirm a CIRS diagnosis or a biotoxin cause.
- VCS test not independently validated: The Visual Contrast Sensitivity test is promoted as a near-universal screening tool for CIRS, yet no large independent study has validated its sensitivity and specificity for biotoxin illness specifically. Critics note it is also sold through the survivingmold.com website - a financial conflict of interest in promoting its use.
- "Any detectable level is abnormal" mycotoxin testing: The CDC specifically called out unvalidated urine mycotoxin testing in a 2014 MMWR report, noting labs were defining their own reference ranges and treating any detectable level as pathological - when low levels of mycotoxins from food alone are found in the urine of healthy individuals.[105]
- MARCoNS clinical significance contested: Coagulase-negative staphylococci colonize the nasal passages of many healthy people. Whether MARCoNS at these sites causes clinically significant illness and whether BEG spray is necessary remains contested outside the Shoemaker community.
- ERMI not validated for individual health decisions: The EPA, which developed the ERMI test, has explicitly stated that ERMI was developed for research purposes and is not intended to be used as a pass/fail test for individual homes or health decisions. Shoemaker's use of ERMI cutoffs for patient management decisions extends beyond the tool's validated purpose.
- Financial ecosystem concerns: The Shoemaker framework generates significant revenue through practitioner certification fees, patient memberships on survivingmold.com, proprietary testing, and the expert witness circuit. Critics argue this creates incentives to promote the CIRS diagnosis even in patients who might have other explanations for their illness.[79]
The Mainstream Medicine Position on Mold and Health
Mainstream medicine does not deny that mold causes illness. It has a very specific and different position on what conditions mold causes and how they should be managed.
- Mold and damp buildings cause respiratory illness: increased asthma, allergic rhinitis, respiratory infections, and perturbation of the immune system. The WHO 2009 Indoor Air Quality guidelines document this comprehensively.[106]
- Occupants of damp or moldy buildings have a 75% greater risk of respiratory symptoms and asthma than occupants of well-maintained buildings.[106]
- Allergic reactions to mold (IgE-mediated) are well-documented and commonly diagnosed by allergists using standardized IgE testing.
- Mold infections in immunocompromised individuals (aspergillosis, candidiasis, cryptococcosis) are well-recognized serious conditions.
- Sick Building Syndrome is a recognized occupational health phenomenon in which building characteristics cause nonspecific symptoms; the CDC and NIOSH investigate building-related illness.
- Removing people from water-damaged environments is a universally recommended public health measure regardless of diagnostic framework.
- That mold causes a specific multi-system inflammatory syndrome with a defined biomarker pattern (CIRS) in genetically susceptible people - this mechanism is not recognized by the CDC, NIH, AAAAI (allergists), AOEC, or any major medical society.
- That "toxic black mold" (Stachybotrys chartarum) causes the full range of symptoms popularly attributed to it (memory loss, chronic fatigue, neurological damage) - the CDC explicitly states there is no conclusive evidence linking indoor mold to these outcomes beyond respiratory illness.
- Urine mycotoxin testing as clinically useful - the CDC recommends against it, noting no validated reference ranges exist and that mycotoxins from food are routinely detectable in healthy people's urine.[105]
- The HLA-based susceptibility model as established - HLA associations with mold sensitivity have not been independently replicated at scale.
Alternative Mold-Illness Approaches (Beyond Shoemaker)
Multiple competing frameworks for understanding and treating mold-related illness exist alongside the Shoemaker model. Each has different assumptions, testing approaches, and treatment philosophies.
Urine Mycotoxin Testing Approach (RealTime Labs, Mosaic Diagnostics/Great Plains)
The most common alternative diagnostic approach: testing urine for mycotoxin metabolites to document internal exposure. Shoemaker himself does not endorse urine mycotoxin testing, arguing it confuses dietary mycotoxin exposure (from food) with inhalation exposure from water-damaged buildings.
- RealTime Laboratories (RTL) - uses competitive ELISA immunoassay; detects 16 mycotoxins including 9 macrocyclic trichothecenes; CAP-accredited; validation study published 2009. Cost: $300-700+ out of pocket. Detects to 0.2 ppb for trichothecenes.
- Mosaic Diagnostics (formerly Great Plains) MycoTOX - uses liquid chromatography-mass spectrometry (LC-MS); detects 11 mycotoxins from 40 mold species; applies creatinine correction for urine concentration. Considered more analytically rigorous method than ELISA.
- Vibrant America - also offers urine mycotoxin panels; LC-MS based.
- No FDA approval for any urine mycotoxin test; CLIA certification only covers analytical quality, not clinical validity[105]
- Reference ranges are set in-house; "any detectable level = positive" is not scientifically defensible since mycotoxins from food are measurable in healthy controls[105]
- Ochratoxin and aflatoxin (tested by RTL) are produced by food-contaminating molds, not reliably indicating building exposure[105]
- Proprietary methods that cannot be independently replicated by other labs - a scientific validity concern
- A positive result may lead to significant, expensive interventions based on findings whose clinical significance is undefined
- Shoemaker's own community considers urine mycotoxin testing misleading and does not use it for CIRS diagnosis
ISEAI: Functional Medicine Approach to Environmentally Acquired Illness
The International Society for Environmentally Acquired Illness (ISEAI) is a nonprofit professional medical society of approximately 350 clinicians, scientists, and Indoor Environmental Professionals (IEPs). ISEAI takes a broader, functional medicine and root-cause approach that is not rigidly tied to the Shoemaker framework, though many ISEAI members also use Shoemaker protocols.[107]
- Recognizes mold illness as one of several possible "environmentally acquired illnesses" alongside toxic chemicals, persistent infections (Lyme, EBV), and heavy metals
- Does not require a specific biomarker panel; uses clinical history and comprehensive functional medicine evaluation
- Emphasizes that multiple exposures often combine - mold rarely operates in isolation from other inflammatory triggers
- Includes both conventional and naturopathic practitioners; more pluralistic than the Shoemaker-only approach
- Publishes a Mold Testing Guide for patients and a Binder Compendium for toxin clearance options beyond cholestyramine
- Activated charcoal - broad-spectrum binder; binds mycotoxins and other toxins; must be taken away from medications and supplements
- Bentonite clay - smectite clay with mycotoxin binding capacity; some evidence for aflatoxin and ochratoxin binding
- GI Detox (zeolite + bentonite + activated charcoal combined) - multi-binder product
- Saccharomyces boulardii - probiotic yeast with documented ochratoxin-binding capacity
- Modified citrus pectin - binds some mycotoxins and heavy metals in the gut
- Chlorella - algae-based binder; some evidence for heavy metals; less evidence for mycotoxins specifically
Finding an ISEAI provider: iseai.org/get-help - international directory of clinicians and Indoor Environmental Professionals.
Bredesen Protocol / ReCODE: Mold as Alzheimer's and Cognitive Decline Driver
Dr. Dale Bredesen, a neurologist at UCLA, developed the ReCODE (Reversal of Cognitive Decline) protocol, which identifies multiple subtypes of cognitive decline including "toxic" or "Type 3" Alzheimer's - in which CIRS from mycotoxin exposure is proposed as a primary driver of neurodegeneration. Bredesen writes that the most common cause of CIRS is mycotoxin exposure from water-damaged buildings.
In practice, ReCODE practitioners treating the toxic subtype use a combination of Shoemaker CIRS biomarkers and testing alongside the broader Bredesen metabolic and nutritional framework. This approach is relevant for ME/CFS patients with significant cognitive decline, as it represents an emerging area at the intersection of mold illness and neurodegenerative risk. Evidence is primarily from Bredesen's own clinical series; large RCTs are lacking.
Nasal and Sinus Colonization Approaches
Some ENT specialists and functional medicine practitioners focus on direct nasal and sinus fungal colonization as a source of ongoing systemic inflammation and mycotoxin exposure - distinct from building exposure. In chronically ill patients with sinus issues, fungi such as Aspergillus and Candida can colonize sinus cavities and generate ongoing inflammatory signals.
- Antifungal nasal rinses - compounded itraconazole or amphotericin B nasal irrigation; used by some otolaryngologists for fungal sinusitis
- Biofilm-disrupting protocols - EDTA-containing nasal sprays (similar to the MARCoNS approach) to disrupt bacterial/fungal biofilms in sinuses
- Culture-guided antifungal treatment - nasal culture or sinus wash cultures identifying specific fungal species; mainstream ENT approach for confirmed fungal sinusitis
- This approach is more accepted by mainstream ENT than CIRS generally, because it treats confirmed fungal presence rather than presumed systemic biotoxin illness
Glutathione Mobilization and Detox Support Protocols
Multiple practitioners use glutathione-based approaches to support mycotoxin detoxification, independently of the formal Shoemaker Protocol. Glutathione is the body's primary intracellular antioxidant and plays a central role in phase II liver detoxification of mycotoxins.
- Liposomal glutathione (oral) - bypasses GI breakdown better than standard oral GSH; brands: Readisorb, Designs for Health Liposomal GSH
- IV glutathione - used by integrative practitioners for rapid systemic delivery; sessions often weekly during active detox
- N-Acetylcysteine (NAC) - glutathione precursor; well-studied; 600-1800mg/day; also has mucolytic and liver-protective effects
- Alpha-lipoic acid - recycles glutathione; also chelates some heavy metals
- Milk thistle (silymarin) - supports hepatic glutathione production
Some practitioners use glutathione as a "provocation" agent before urine mycotoxin testing, claiming it releases stored mycotoxins. This is specifically criticized by multiple sources: it can produce false-positive or misleadingly elevated results and is not a validated clinical practice. Labs themselves warn against provocation before testing.
The WHO / Mainstream Public Health Approach to Damp Buildings
The World Health Organization published comprehensive guidelines on indoor air quality, dampness, and mold in 2009. These represent the mainstream international public health position and are distinct from both the CIRS framework and the alternative functional medicine approaches.[106]
- Dampness in buildings is associated with a 50% increase in current asthma; 21% of asthma in the US may be attributable to residential dampness and mold
- Occupants of damp buildings have 75% greater risk of respiratory symptoms compared to well-maintained buildings
- Key effects: increased respiratory symptoms, allergies, asthma, and perturbation of the immune system
- The primary intervention is environmental remediation and moisture control - not medical treatment of the occupant
- Mold identification: visual inspection is the primary recommended method; air sampling has significant limitations including not capturing settled spore DNA
- Mold in buildings is a genuine health hazard requiring remediation
- Removing people from damp buildings improves health outcomes
- Prevention through moisture control is the most important public health measure
- Low-income and rented housing has disproportionately higher damp and mold burden - an environmental justice issue
- WHO does not recognize CIRS as a distinct syndrome
- WHO does not endorse specific biomarker panels or the 12-step treatment protocol
- WHO does not endorse HLA susceptibility testing for mold illness
- WHO does not recommend urine mycotoxin testing
A Practical Patient Framework: How to Approach This
- Inspect your home and workplace for water damage, visible mold, and musty odors
- If found, have professional remediation performed by a certified IICRC remediator
- Use HEPA air purifiers in your living space
- Control humidity below 50% with dehumidifiers and proper ventilation
- If symptoms improve dramatically when away from a specific building for 1-2 weeks, take this seriously as a clinical signal
- Ensure adequate glutathione precursors (NAC, B vitamins, minerals) to support detox pathways
- HERTSMI-2 or ERMI building test if building history is uncertain - knowing your environment matters even if clinical interpretation is debated
- VCS test as a free or low-cost screening step before spending more on blood panels
- Shoemaker CIRS biomarker panel if you have a suspected environmental exposure, an ME/CFS-knowledgeable physician willing to interpret results, and the financial resources - with the understanding that these markers are not standardized or independently validated
- Trial of binders (activated charcoal, cholestyramine) while addressing environment - limited risk if done correctly and monitored
- Urine mycotoxin testing as the primary diagnostic tool - evidence limitations are significant; do not make major life decisions based on this alone
- Glutathione provocation before urine testing - not a validated method
- Any practitioner who diagnoses CIRS based on online questionnaires or urine tests alone without thorough clinical evaluation
- VIP nasal spray (Step 12) from compounding pharmacies without established CIRS diagnosis and appropriate medical supervision - this is a hormonal intervention
- Very high out-of-pocket treatment costs before environmental remediation has been completed - removing the exposure must come first